DEFA14A: MidCap Financial Investment Corporation Amends Proxy Statement with Updated Director Attendance and Committee Details
Proxy Statement Supplement
MidCap Financial Investment Corporation filed a supplement to its definitive proxy statement, updating disclosures related to director attendance at board and committee meetings and detailing the composition and responsibilities of its key committees for the upcoming 2025 Annual Meeting of Stockholders.
Summary
- This supplement, dated June 9, 2025, amends and restates specific disclosures in the Definitive Proxy Statement filed on April 29, 2025, concerning director attendance and committee information.
- For the fiscal year ended December 31, 2024, the Board held five board meetings, four Audit Committee meetings, four Nominating and Corporate Governance Committee meetings, and one Compensation Committee meeting.
- Each Director attended at least 75% of the combined number of Board and committee meetings during the fiscal year ended December 31, 2024.
- All Directors attended the 2024 annual meeting of stockholders virtually.
- The Audit Committee, Nominating and Corporate Governance Committee, and Compensation Committee are composed of Independent Directors: Messrs. Pearlman, Reinfrank, Stein, and Ms. Matas.
- Ms. Matas chairs the Audit Committee, and Messrs. Pearlman and Reinfrank and Ms. Matas qualify as audit committee financial experts.
- Mr. Stein chairs the Nominating and Corporate Governance Committee.
- A new Co-Investment Committee has been established, comprised of all Independent Directors, responsible for reviewing and approving co-investment transactions pursuant to an exemptive order received on May 14, 2025.
Sentiment
Score: 5
Explanation: The document is a neutral, factual update on corporate governance and director attendance, with no explicit positive or negative financial implications or strategic shifts.
Positives
- Each Director attended at least 75% of the combined Board and committee meetings for the fiscal year ended December 31, 2024, indicating strong engagement.
- The Board has established clear charters for its Audit, Nominating and Corporate Governance, and Compensation Committees, promoting structured oversight.
- The identification of three audit committee financial experts (Messrs. Pearlman, Reinfrank, and Ms. Matas) enhances financial oversight capabilities.
- The establishment of a Co-Investment Committee, following an exemptive order from the SEC, allows for specific oversight of co-investment transactions.
Future Outlook
The document indicates that the composition of the Audit Committee, Nominating and Corporate Governance Committee, and Compensation Committee, comprising Messrs. Pearlman, Reinfrank, and Stein and Ms. Matas, will be effective after the 2025 Annual Meeting of Stockholders.
Industry Context
This filing is a routine corporate governance update common among publicly traded companies, particularly investment companies, to ensure transparency and compliance with SEC regulations and NASDAQ listing standards regarding board and committee structures and director qualifications. The establishment of a Co-Investment Committee is specific to investment companies operating under certain SEC exemptive orders, allowing them to engage in co-investment activities with affiliates.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Disclosure Amendment | Amends and restates disclosure regarding director attendance at Board and committee meetings for the fiscal year ended December 31, 2024. | June 9, 2025 | Enhances transparency regarding board oversight and director engagement. |
| Committee Structure Update | Details the composition and responsibilities of the Audit Committee, Nominating and Corporate Governance Committee, and Compensation Committee, effective after the 2025 Annual Meeting. | After 2025 Annual Meeting | Clarifies roles and membership of key oversight committees, ensuring compliance with independence requirements. |
| New Committee Establishment | Formation of a Co-Investment Committee, comprised of all Independent Directors, to review and approve co-investment transactions pursuant to an SEC exemptive order. | May 14, 2025 (Order date) | Provides dedicated oversight for specific investment activities, enhancing governance around potential conflicts of interest in co-investments. |
| Director Qualification Disclosure | Identifies Messrs. Pearlman and Reinfrank and Ms. Matas as audit committee financial experts. | June 9, 2025 | Ensures compliance with regulatory requirements for financial expertise on the Audit Committee. |
| Director Nomination Process Clarification | Reiterates the process for stockholder recommendations for director nominees, including required information and criteria considered by the Nominating and Corporate Governance Committee. | June 9, 2025 | Provides clear guidelines for shareholder participation in the director nomination process. |
| Diversity Consideration Policy | States that while there is no formal policy, the Nominating and Corporate Governance Committee may consider diversity (professional experience, education, skills, gender, race, national origin) in identifying director candidates. | June 9, 2025 | Reflects evolving corporate governance best practices regarding board diversity, aiming for a broader range of perspectives. |
Stakeholder Impact
- Shareholders: Provided updated information for voting decisions at the 2025 Annual Meeting, particularly regarding corporate governance and director qualifications.
Next Steps
- Stockholders to read the Supplemental Disclosure in conjunction with the original Proxy Statement for voting decisions at the 2025 Annual Meeting of Stockholders.
- The 2025 Annual Meeting of Stockholders will proceed with the proposals as outlined in the Proxy Statement.
- The specified Independent Directors will serve on the Audit, Nominating and Corporate Governance, and Compensation Committees after the 2025 Annual Meeting.
Key Dates
| Date | Description |
|---|---|
| December 31, 2024 | End of fiscal year for which director and committee meeting attendance is reported. |
| April 29, 2025 | Date of the original Definitive Proxy Statement filing. |
| May 14, 2025 | Date the Company received an exemptive order from the SEC for co-investment transactions. |
| June 9, 2025 | Date of this Proxy Statement Supplement. |
| 2025 Annual Meeting of Stockholders | Upcoming meeting where proposals will be acted upon and committee compositions will be effective. |
Keywords
SEC Filing, Proxy Statement, Corporate Governance, Board of Directors, Audit Committee, Nominating and Corporate Governance Committee, Compensation Committee, Co-Investment Committee, Director Attendance, Shareholder Meeting, MidCap Financial Investment Corporation, Investment Company, Form 14A
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.